Chris@CNW, Author at CannabisNewsWire

TuesdayMar 14, 2017 4:00 pm

Intec Pharma Ltd. (NASDAQ: NTEC) Starts Presentation at 29th Annual ROTH Conference

Intec Pharma (NASDAQ: NTEC) is a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of drugs by utilizing an efficient gastric retention and specific release mechanism. The company's product pipeline currently includes three product candidates in clinical trial stages: Accordion Pill Carbidopa/Levodopa, currently in phase III; Accordion Pill Zaleplon; and an Accordion Pill that is being developed for the prevention and treatment of gastroduodenal and small bowel ulcers induced by Nonsteroidal Anti-Inflammatory Drugs. In addition,…

TuesdayMar 14, 2017 10:41 am

India Globalization Capital, Inc. (NYSE: IGC) is “One to Watch”

India Globalization Capital, Inc. (NYSE MKT: IGC) is a first mover in developing a portfolio of products using cannabis-based “combination therapies” for the treatment of pain and other conditions. The national cost of health care due to pain ranges from $560 billion to $635 billion. In addition, the health care cost attributed to the abuse of prescription opioids, closely related to pain, is approximately $25 billion. IGC’s patent filing (IGC-501) is a cannabis-based formulation addressing neuropathic and arthritic pain in joints and muscles using a variety of delivery techniques. The Company anticipates commencing clinical trials, and hopes that through its…

MondayMar 13, 2017 4:00 pm

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) Starts Presentation at 29th Annual Roth Conference

Zynerba Pharmaceuticals (NASDAQ: ZYNE) is a specialty pharmaceutical company that focuses on developing and commercializing proprietary synthetic cannabinoid therapeutics formulated for transdermal delivery. The company’s product candidates include ZYN002, which is in Phase I clinical trial for the treatment of refractory epilepsy, Fragile X syndrome, and osteoarthritis; and ZYN001 that is in preclinical stage for the treatment of fibromyalgia and peripheral neuropathic pain. For more information, visit the company’s website at www.zynerba.com. About CannabisNewsWire CannabisNewsWire (CNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution…

MondayMar 13, 2017 4:00 pm

Nuvectra Corp. (NASDAQ: NVTR) Starts Presentation at 29th Annual ROTH Conference

Nuvectra (NASDAQ: NVTR) is a neuromodulation medical device company that develops and commercializes its neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets in Europe. The company’s Algovita spinal cord stimulation system is used for the treatment of chronic pain of the trunk and limbs. It also provides neural interface technology, components, and systems, as well as NeuroNexus SmartBox portable control and data streaming systems. The company is based in Plano, Texas. For more information, visit the company’s website at www.nuvectramed.com. About CannabisNewsWire CannabisNewsWire (CNW) provides news aggregation and syndication, enhanced press release services and…

FridayMar 10, 2017 3:22 pm

The Diversified Domain of Easton Pharmaceuticals, Inc. (EAPH)

Drug development. Medical marijuana. Female diagnostics and treatments. These high-growth industries and sectors are the focal points of Easton Pharmaceuticals, Inc.’s (OTC: EAPH) operations. A diversified and specialty company based in Canada, Easton’s operation spans multiple pharmaceutical sectors and other emergent industries, including the medical marijuana market. In its day-to-day operations, the company balances three mission goals: It develops and acquires drugs, diagnostics and treatment products that build shareholder value. It delivers safe, effective and proven products that improve the health and well-being of men and women across global jurisdictions. It builds and capitalizes on fast-growing and promising industries and…

FridayMar 10, 2017 9:11 am

Singlepoint, Inc. (SING) Showing Growth through Its Strategic Acquisition Plan

Singlepoint, Inc. (OTC: SING), a publicly traded holding company based in Arizona, has been highlighted as one to look out for in the cannabis space, according to InsiderFinancial.com (http://nnw.fm/f5UrR). The company, through its SingleSeed subsidiary, provides business services to cannabis businesses, including marketing, point of sale and more. Because of the company’s nature, and its ability to fill a very challenging gap in the marijuana industry, Singlepoint is on a climb as the industry continues to flourish in the United States. This has been reflected in its stock price, which at the time of InsiderFinancial’s coverage had shown a 560%…

WednesdayMar 08, 2017 8:30 am

Strong Technical Interface Making Cannabis Industry More Profitable and Efficient

Any fast-growing business needs an operational framework to help it develop and better serve its customers, and the marijuana industry is no different. As the legal cannabis market continues its impressive expansion, a growing number of companies are emerging to form a legal support framework of related technology and ancillary services that are driving the industry toward an efficient and profitable structure. Companies such as SinglePoint, Inc. (SING) (SING Profile), MassRoots, Inc. (MSRT), mCig. Inc. (MCIG), Rocky Mountain High Brands, Inc. (RMHB) and Innovative Industrial Properties, Inc. (IIPR) are branching out into different segments of the industry, determined to make…

TuesdayMar 07, 2017 9:14 am

SeeThruEquity Issues Update on ChineseInvestors.com (CIIX), Increases Price Target to $3.75

Less than two weeks after making a presentation at the SeeThruEquity Conference in Miami Beach, SeeThruEquity increased its price target for ChineseInvestors.com (OTCQB: CIIX) to $3.75. The previous price target for CIIX, issued in October 2016, was $2.05. SeeThruEquity delivers unbiased and unpaid for equity research for publicly traded companies with market capitalizations of less than $1 billion. The increased target price reflects the added potential from legal cannabis initiatives taken by ChineseInvestors.com. Though in the early stages of penetrating the legal cannabis market, ChineseInvestors.com has demonstrated prior success with its profitable investment in Medicine Man Technologies, generating $2.3 million…

MondayMar 06, 2017 9:52 am

InMed Pharmaceuticals, Inc. (IMLFF) is “One to Watch”

InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company’s cannabinoid biosynthesis technology and drug development pipeline, serves as InMed’s fundamental value driver. Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases,…

ThursdayMar 02, 2017 3:34 pm

India Globalization Capital, Inc. (NYSE MKT: IGC) Targets Cannabis-Based Pharmaceuticals

India Globalization Capital, Inc. (NYSE MKT: IGC) is a company in transition, now targeting pharmaceutical development in the U.S., while curtailing other businesses such as electronics trading in Hong Kong. IGC long-term plans are to establish and extend its development of phytocannabinoid-based pharmaceutical products to treat diseases such as epilepsy and cachexia. The company expects to file more patents and develop additional intellectual property in the health care industry. In the U.S., IGC develops phytocannabinoid-based treatments for epilepsy, seizures and cachexia. The goal in 2017, per CEO Ram Mukunda, is for the company to expand its cannabis-based portfolio, indicating that…